

Next Frontier in Healthcares – Stem Cells and Cell therapies

Pradeep V. Mahajan

Chairman & Managing Director, StemRx Bioscience Solutions Pvt. Ltd, India

Abstract

The concept of mesenchymal stem cells (MSC) being proposed as a medicinal signaling agent is based on the fact that cells are not single molecular agents. MSCs, which more appropriately may be called 'Living Drug' molecules, are adaptive agents capable of complex functions involving many bioactive factors. These multi-potent cells may be considered injury-specific drug stores that home to the site of injury and secrete considerable levels of immunomodulatory and trophic factors.

MSCs reduce inflammation, modulate the immune system, as well as stimulate other cells to perform their functions effectively (paracrine properties). In addition, MSCs can function as regulated delivery vehicles and target specific molecules that act against cancerous cells. This could be an interesting avenue of research in cancer immunotherapy, to enhance the outcomes of dendritic and natural killer cell therapies.

Received: June 10, 2022; **Accepted:** June 17, 2022; **Published:** June 27, 2022

Biography

Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra and went on to pursue Diploma in Urology at the University of Vienna, Austria. In a career changing move, after three decades of being a successful general and uro-surgeon.

Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra and went on to pursue Diploma in Urology at the University of Vienna, Austria. In a career changing move, after three decades of being a successful general and uro-surgeon, he started his brainchild - StemRx Bioscience